Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Yazeed Sawalha, Rina Li Welkie, Anna Krivenko, Brian Hess, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John C Reneau, Narendranath Epperla, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert Baiocchi, Kami J. Maddocks

Blood (2023) 142 (Supplement 1): 6226.

https://doi.org/10.1182/blood-2023-182941

Published: 2023

Journal Articles

Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Allison M Lehanka, Ann Kebede, Neda Amirmokhtari, Joseph R Stanek, Narendranath Epperla, Beth Christian, Robert Baiocchi, Timothy Voorhees, Kami J. Maddocks, Yazeed Sawalha, John C Reneau, Jonathan E. Brammer, Audrey M. Sigmund, Faye Willen, Nick Yeager, Anthony N. Audino, David A. Bond

Blood (2023) 142 (Supplement 1): 3116.

https://doi.org/10.1182/blood-2023-187194

Published: 2023

Journal Articles

Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-Cell Lymphomas

Zachary Braunstein, Allyson Waller, Emily Dotson, Eric McLaughlin, Walter Hanel, John C Reneau, Daniel Addison, Pierluigi Porcu, Jonathan E. Brammer

Blood (2023) 142 (Supplement 1): 4453.

https://doi.org/10.1182/blood-2023-184583

Published: 2023

Journal Articles

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with T-Cell Malignancies: Final Results of a Phase I/II Trial

Blood (2023) 142 (Supplement 1): 184.

https://doi.org/10.1182/blood-2023-190213

Published: 2023

Journal Articles

Real-World Evaluation of T-Prolymphocytic Leukemia Outcomes Using the 2019 T-PLL International Study Group Criteria

Zachary Braunstein, Eric McLaughlin, Anjali Mishra, Pierluigi Porcu, Jonathan E. Brammer

Blood (2023) 142 (Supplement 1): 6213.

https://doi.org/10.1182/blood-2023-184602

Published: 2023

Journal Articles

A Multicenter Real-World Analysis (RWA) of Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) Treated in the Modern Era

Deepa Jagadeesh, Stefan K. Barta, Jonathan E. Brammer, Wei Wei, Julie E Chang, Rahul Mishra, Tavakkoli Montreh, Alma Habib, Marcus P Watkins, Yash Deshmukh, Sharina C Macapagal, Madiha Iqbal, N. Nora Bennani, Frederick Lansigan, Neha Mehta-Shah

Blood (2023) 142 (Supplement 1): 6177.

https://doi.org/10.1182/blood-2023-191176

Published: 2023

Journal Articles

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Jonathan E. Brammer, Karen Ballen, Lubomir Sokol, Christiane Querfeld, Ryotaro Nakamura, Anjali Mishra, Eric M. McLaughlin, David Feith, Nazli Azimi, Thomas A. Waldmann, Yutaka Tagaya, Thomas Loughran

Blood (2023) 142 (15): 1271–1280.

https://doi.org/10.1182/blood.2022017643

Published: 2023

Includes: Supplemental data

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Eric D Jacobsen, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Marci Daugherty, Jonathan E Brammer, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz

Blood (2022) 140 (Supplement 1): 9387–9389.

https://doi.org/10.1182/blood-2022-169432

Published: 2022

Journal Articles

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Yuqin Song, Ning Ding, Dok Hyun Yoon, John C. Reneau, Ryan A. Wilcox, Won Seog Kim, Youn H. Kim, Michael S. Khodadoust, Tatyana A. Feldman, Costas K. Yannakou, Pratyush Giri, Jonathan E Brammer, Lih-Yun Hsu, Hongwei Yuan, Erik Verner, Suresh Mahabhashyam, Richard A. Miller

Blood (2022) 140 (Supplement 1): 8857–8859.

https://doi.org/10.1182/blood-2022-159177

Published: 2022

Journal Articles

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1481–1484.

https://doi.org/10.1182/blood-2022-160090

Published: 2022

Journal Articles

Therapeutic Potential and Role of CD38 in Cutaneous T-Cell Lymphoma Pathogenesis

Colleen Isabelle, Kathleen McConnell, Amy E Boles, Jonathan E Brammer, Robyn Berge, Carla Portocarrero, Nitin Chakravarti, Pierluigi Porcu, Neda Nikbakht, Anjali Mishra

Blood (2022) 140 (Supplement 1): 9216–9218.

https://doi.org/10.1182/blood-2022-170550

Published: 2022

Journal Articles

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Blood (2022) 140 (Supplement 1): 1885–1886.

https://doi.org/10.1182/blood-2022-169336

Published: 2022

Journal Articles

Effect of Age on Outcomes of Allogeneic Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood (2021) 138 (Supplement 1): 3933.

https://doi.org/10.1182/blood-2021-146334

Published: 2021

Journal Articles

Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial

Blood (2021) 138 (Supplement 1): 553.

https://doi.org/10.1182/blood-2021-152833

Published: 2021

Journal Articles

Efficient Targeting of CD38 in Mature T-Cell Neoplasms with Daratumumab and Allogeneic NK Cells

William T. Johnson, Colleen Isabelle, Ashley N Vogel, Jonathan E Brammer, Amy E Boles, Kathleen McConnell, Robyn Berge, Liam Nisenfeld, Guldeep Uppal, Jerald Gong, Nitin Chakravarti, Pierluigi Porcu, Anjali Mishra

Blood (2021) 138 (Supplement 1): 2408.

https://doi.org/10.1182/blood-2021-154234

Published: 2021

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis

Jonathan E Brammer, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Eric D Jacobsen, Giuseppe Gritti, Debra Litwak, David Cohan, Danica J Katz, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz

Blood (2021) 138 (Supplement 1): 2456.

https://doi.org/10.1182/blood-2021-148939

Published: 2021

Journal Articles

Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias

Zachary Braunstein, Miguel Ruiz, Eric McLaughlin, Naresh Bumma, Don M Benson, Jr., Srinivas Devarakonda, Maria Chaudhry, Abdullah Khan, Francesca Cottini, John C. Reneau, Pierluigi Porcu, Anjali Mishra, Ashley E. Rosko, Jonathan E Brammer

Blood (2021) 138 (Supplement 1): 2449.

https://doi.org/10.1182/blood-2021-152556

Published: 2021

Journal Articles

Cyclophosphamide Induces Durable Molecular and Clinical Responses in Patients with Relapsed T-Large Granular Lymphocytic Leukemia (T-LGLL)

Zachary Braunstein, Eric McLaughlin, Anjali Mishra, Jonathan E Brammer

Blood (2021) 138 (Supplement 1): 2471.

https://doi.org/10.1182/blood-2021-147624

Published: 2021

Journal Articles

Utilizing Organ-Sparing Marrow Irradiation to Condition Patients Prior to Allogeneic Hematopoietic Cell Transplant with High-Risk Hematologic Malignancies: Results of a Pilot Study

Sumithira Vasu, Meghan Kromer, Qiuhong Zhao, Hannah Choe, Karilyn Larkin, Sarah A Wall, Samantha Jaglowski, Sam Penza, Jonathan E Brammer, Nidhi Sharma, Naduparambil Jacob, Marcos J.G. de Lima, Meng Welliver

Blood (2021) 138 (Supplement 1): 2856.

https://doi.org/10.1182/blood-2021-150948

Published: 2021

Journal Articles

Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution

Audrey M. Sigmund, Nathan Denlinger, Amneet Bajwa, Patrick Elder, David A. Bond, Jonathan E Brammer, Ayman Saad, Sam Penza, Marcos J.G. de Lima, Samantha Jaglowski, Adam S Kittai

Blood (2021) 138 (Supplement 1): 3851.

https://doi.org/10.1182/blood-2021-148751

Published: 2021

NARROW

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-Cell Lymphomas

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with T-Cell Malignancies: Final Results of a Phase I/II Trial

Real-World Evaluation of T-Prolymphocytic Leukemia Outcomes Using the 2019 T-PLL International Study Group Criteria

A Multicenter Real-World Analysis (RWA) of Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) Treated in the Modern Era

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Therapeutic Potential and Role of CD38 in Cutaneous T-Cell Lymphoma Pathogenesis

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Effect of Age on Outcomes of Allogeneic Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial

Efficient Targeting of CD38 in Mature T-Cell Neoplasms with Daratumumab and Allogeneic NK Cells

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis

Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias

Cyclophosphamide Induces Durable Molecular and Clinical Responses in Patients with Relapsed T-Large Granular Lymphocytic Leukemia (T-LGLL)

Utilizing Organ-Sparing Marrow Irradiation to Condition Patients Prior to Allogeneic Hematopoietic Cell Transplant with High-Risk Hematologic Malignancies: Results of a Pilot Study

Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only